The Manager - Listing
The National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G. Block
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051
Scrip Code: EMAMILTD

The Manager - Listing BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001
Scrip Code: 531162

Dear Sirs,

Pursuant to Provision of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copy of Presentation on Company's Performance update for the quarter ended 30th September, 2022.

The aforesaid information is also disclosed on the website of the company www.emamiltd.in.

This is for your information and records.

Thanking you,

Yours faithfully,
For Emami Limited

ASHOK
PUROHIT

## Ashok Purohit

Dy. Company Secretary \& DGM- Legal
(Encl. : As above)

## BOROPLUS

# O2 \& H1FY23 Performance Update $11^{\text {th }}$ November 2022 

## Q2 \& H1 Revenue Growth

| Particulars |  | Q2FY23 Growth [\%] |  | H1FY23 Growth [\%] |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
|  |  | 3year CAGR | Over PY | 3 year CAGR |  |
| - Domestic Business | $1 \%$ | $8 \%$ | $7 \%$ | $7 \%$ |  |
| - International Business | $17 \%$ | $8 \%$ | $30 \%$ | $9 \%$ |  |
| Consolidated Net Sales | $\mathbf{4 \%}$ | $\mathbf{8 \%}$ | $\mathbf{1 0 \%}$ | $\mathbf{7 \%}$ |  |
| - Other Operating Income | $-36 \%$ | $-18 \%$ | $0 \%$ | $\mathbf{- 8 \%}$ |  |
| Total Revenues | $3 \%$ | $\mathbf{7 \%}$ | $\mathbf{1 0 \%}$ | $\mathbf{7 \%}$ |  |

- Helios Lifestyle Pvt. Ltd (The Man Company] became a Subsidiary of Emami Ltd w.e.f. $1^{\text {st }}$ July'22 and contributed 3.5\% to Consolidated Net Sales in 02FY23
$\square$ Correction in Pain Management and Healthcare range on expected lines due to exceptionally high base in last year
Net sales growth of 8\% excluding Pain Management, Healthcare range and Helios in 02FY23.


## Modern Channels continue to perform well

## Modern Trade



H1FY23 Growth 34\%

## E-Commerce



## Brand/ Business Performance analysis

Domestic brand wise \& International sales performance analysis in Q2 \& H1FY23

## BoroPlus Range

- Sales grew by $17 \%$ in 02 and by $14 \%$ in H1FY23
- Introduced new packaging for BoroPlus SOFT Ayurvedic Antiseptic Cream in tub format and 10 ml tub for BoroPlus Antiseptic Cream
- Roped in Bollywood superstar Akshay Kumar to endorse BoroPlus Antiseptic cream



## Navratna Range

- Sales declined by 5\% in 02;
- However, sales grew by 15\% in H1FY23
- Continued BTL activations in H1FY23
- $15+$ vans covering $3000+$ villages and 600+ haats - 12 lac+ samples distributed
- 42000 salons covered across 60+ cities with 10 lac+ samples distributed
- Participated in 19 fairs with ~47 lac samples distributed
- Digital activations on various platforms to build strong association of Champi with Navratna


Launched new campaign in Telugu, Kannada, Tamil \& Malayalam for southern markets to target new users

## Male Grooming Range

$\triangleright$ Sales grew by 2\% in @2; 16\% growth in H1FY23
$\triangleright$ Fair and Handsome relaunched during the quarter

- Packaging Revamp - Vibrant/ clutter breaking packaging design - Clear differentiation between new and old pack on shelf
- Communication Refresh (New TVC + Digital Amplification] -
- New TVC communicating the key proposition of Handsomegirii.e. looking and doing good at the same time
- Digital Content Creation - Voxpop Video
- Website Revamp
- Ecommerce \& Social Media activation



## Pain Management Range

- Sales corrected by $\mathbf{1 3 \%}$ in $\mathbf{Q 2}$ and by $\mathbf{2 1 \%}$ in H1FY23
- Delivered growth of $20 \%$ in Q 2 and $26 \%$ in H 1 this year compared to pre-COVID period Cover Q2FY20 and HIFY20)
- 3 year CAGR of $6 \%$ in Q 2 and $8 \%$ in H 1 .
- Launched 100 ml SKU for Zandu Balm
- Launched Zandu Fast Relief Gel in Aug'22 across channels
- Endorsed by Dr. Ali Irani, ex-physio Team India



## Healthcare Range

- Sales corrected by $\mathbf{1 6 \%}$ in $\mathbf{0 2}$ and by $\mathbf{2 0 \%}$ in H1FY23
- Delivered growth of $34 \%$ in Q 2 and $39 \%$ in H 1 this year compared to pre-COVID period (over Q2FY20 and HIFY20) - 3 year CAGR of $10 \%$ in Q 2 and $12 \%$ in HI .

D D2C portal Zanducare performing well despite drop in demand for immunity products

- Digital First NPD's showing good traction;
- Launched "Zandu Organic apple cider vinegar" powered with potent herbs like Ashwagandha, Garcinia and Saffron for myriad health benefits



## Kesh King Range

- Sales declined by $\mathbf{1 0 \%}$ in $\mathbf{Q 2}$ but grew by 3\% in H1FY23
- High base of $28 \%$ growth for last 2 years (Q2FY22 \& Q2FY21)
- 3 year CAGR of 14\% in Q2FY23
- Launched new campaign for Kesh King Shampoo with Ali Fazal
- Building Kesh King shampoo sachet through trade offers and sampling activity

- New launch - Kesh King Onion Range performing well.


## Digital first launches

## 7 Oils in One Organics Zandu Organic Apple Cider Vinegar

## Zandu Fast Relief Gel



Launched in Aug'22 across channels


Launched in Sep'22


Organic apple cider vinegar powered with potent herbs like Ashwagandha, Garcinia and Saffron for myriad health benefits

## New Campaigns



## Digital Campaigns



The oil that keeps your hair All-day Set, ROUND


## International Business

- Sales grew by $17 \%$ in Q2 \& by 30\% in H1FY23


## International Business Region wise sales salience

- Strong growth from MENA in Q2FY23
- CIS continued to grow despite disturbances
- Other SAARC markets including Nepal, Sri Lanka etc are showing signs of recovery despite continued macro-economic issues.


SAARC South Asian Association for Regional Cooperation (Major countries - Bangladesh, Nepal, Sri Lanka etc.)
MENA Middle East \& North Africa (Major countries - KSA, UAE, Qatar, Oman, Kuwait, Bahrain etc.)
CIS Commonwealth of Independent States (Major Countries - Russia, Ukraine etc.)

## Q2FY23 Profitability (Consolidated)

| Financials | Q2FY23 |  |  |  | H1FY23 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | ₹ in crore | Growth | $\begin{aligned} & 3 \mathrm{yr} \\ & \text { CAGR } \end{aligned}$ | Margins | ₹ in crore | Growth | $\begin{gathered} 3 \mathrm{yr} \\ \text { CAGR } \end{gathered}$ | Margins |
| Revenues | 814 | 3\% | 7\% |  | 1,587 | 10\% | 7\% |  |
| COGS | 271 | 11\% | 11\% | 33.4\% | 558 | 19\% | 9\% | 35.1\% |
| Gross Profit | 542 | 0\% | 6\% | 66.6\% | 1,029 | 5\% | 5\% | 64.9\% |
| A\&P Spends | 141 | 34\% | 10\% | 17.4\% | 278 | 29\% | 6\% | 17.5\% |
| EBIDTA | 195 | -30\% | 0\% | 24.0\% | 369 | -17\% | 4\% | 23.2\% |
| PAT | 180 | -3\% | 23\% | 22.1\% | 253 | -4\% | 23\% | 15.9\% |

Gross Margin decline due to inflationary pressure and favorable portfolio mix in PY
3 year CAGR EBIDTA growth of 4\% in H1 despite aggressive investments behind brands

## Q2FY23 Financial Analysis



## H1FY23 Financial Analysis



## Q2FY23 Consolidated Financials

| Particulars | Q2FY23 | \% | Q2FY22 | \% | Growth | FY22 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 8,073.6 | 99.2\% | 7,771.0 | 98.7\% | 3.9\% | 31,570.4 | 98.9\% |
| Other Operating Income | 63.9 | 0.8\% | 100.2 | 1.3\% | -36.2\% | 349.9 | 1.1\% |
| Revenue from Operations | 8,137.5 | 100.0\% | 7,871.2 | 100.0\% | 3.4\% | 31,920.3 | 100.0\% |
| Materials Cost | 2,715.7 | 33.4\% | 2,446.6 | 31.1\% | 11.0\% | 10,778.8 | 33.8\% |
| A\&P | 1,414.8 | 17.4\% | 1,053.2 | 13.4\% | 34.3\% | 5,229.0 | 16.4\% |
| Staff Cost | 934.7 | 11.5\% | 820.7 | 10.4\% | 13.9\% | 3,177.7 | 10.0\% |
| Admin \& Other Expenses | 1,118.5 | 13.7\% | 778.9 | 9.9\% | 43.6\% | 3,211.1 | 10.1\% |
| EBIDTA | 1,953.8 | 24.0\% | 2,771.8 | 35.2\% | -29.5\% | 9,523.7 | 29.8\% |
| Other Income | 419.9 | 5.2\% | 376.1 | 4.8\% | 11.6\% | 952.5 | 3.0\% |
| Interest | 17.6 | 0.2\% | 7.8 | 0.1\% | 125.6\% | 50.7 | 0.2\% |
| Amortisation of acquired TM's/brands | 234.6 | 2.9\% | 602.7 | 7.7\% | -61.1\% | 2,405.7 | 7.5\% |
| Depreciation/Amortisation of other assets | 244.7 | 3.0\% | 236.1 | 3.0\% | 3.6\% | 942.1 | 3.0\% |
| PBT before Exceptional Items | 1,876.8 | 23.1\% | 2,301.3 | 29.2\% | -18.4\% | 7,077.7 | 22.2\% |
| Share of Profit / Closs) of associate | (21.6) | -0.3\% | (38.4) | -0.5\% | -43.8\% | (145.8) | -0.5\% |
| Exceptional Items | - | 0.0\% | - | 0.0\% | 0.0\% | (51.8) | -0.2\% |
| PBT | 1,855.2 | 22.8\% | 2,262.9 | 28.7\% | -18.0\% | 6,880.1 | 21.6\% |
| Tax | 53.9 | 0.7\% | 410.4 | 5.2\% | -86.9\% | (1,486.6) | -4.7\% |
| PAT | 1,801.3 | 22.1\% | 1,852.5 | 23.5\% | -2.8\% | 8,366.7 | 26.2\% |
| Non controlling interest | (40.5) | -0.5\% | (0.2) | 0.0\% | -100.0\% | (23.2) | -0.1\% |
| Profit for the Period | 1,841.8 | 22.6\% | 1,852.7 | 23.5\% | -0.6\% | 8,389.9 | 26.3\% |
| Adjusted PAT | 2,076.4 | 25.5\% | 2,455.4 | 31.2\% | -15.4\% | 8,544.1 | 26.8\% |

*Adjusted PAT = Reported PAT + Exceptional Items + Amortization of Kesh King \& other brand related intangible assets. For FY22, it also excludes, MAT credit 18 entitlement of previous years

| Particulars | H1FY23 | \% | H1FY22 | \% | Growth | FY22 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 15,703.2 | 98.9\% | 14,312.4 | 98.8\% | 9.7\% | 31,570.4 | 98.9\% |
| Other Operating Income | 167.4 | 1.1\% | 167.3 | 1.2\% | 0.1\% | 349.9 | 1.1\% |
| Revenue from Operations | 15,870.6 | 100.0\% | 14,479.7 | 100.0\% | 9.6\% | 31,920.3 | 100.0\% |
| Materials Cost | 5,576.6 | 35.1\% | 4,691.8 | 32.4\% | 18.9\% | 10,778.8 | 33.8\% |
| A\&P | 2,777.8 | 17.5\% | 2,151.8 | 14.9\% | 29.1\% | 5,229.0 | 16.4\% |
| Staff Cost | 1,822.6 | 11.5\% | 1,665.7 | 11.5\% | 9.4\% | 3,177.7 | 10.0\% |
| Admin \& Other Expenses | 2,006.6 | 12.6\% | 1,501.5 | 10.4\% | 33.6\% | 3,211.1 | 10.1\% |
| EBIDTA | 3,687.0 | 23.2\% | 4,468.9 | 30.9\% | -17.5\% | 9,523.7 | 29.8\% |
| Other Income | 483.2 | 3.0\% | 483.3 | 3.3\% | 0.0\% | 952.5 | 3.0\% |
| Interest | 42.5 | 0.3\% | 14.2 | 0.1\% | 199.3\% | 50.7 | 0.2\% |
| Amortisation of acquired TM's/brands | 874.1 | 5.5\% | 1,198.8 | 8.3\% | -27.1\% | 2,405.7 | 7.5\% |
| Depreciation/Amortisation of other assets | 486.3 | 3.1\% | 470.0 | 3.2\% | 3.5\% | 942.1 | 3.0\% |
| PBT before Exceptional Items | 2,767.3 | 17.4\% | 3,269.2 | 22.6\% | -15.4\% | 7,077.7 | 22.2\% |
| Share of Profit / [loss) of associate | (65.3) | -0.4\% | (53.6) | -0.4\% | 21.8\% | (145.8) | -0.5\% |
| Exceptional Items | - | 0.0\% | - | 0.0\% | 0.0\% | (51.8) | -0.2\% |
| PBT | 2,702.0 | 17.0\% | 3,215.6 | 22.2\% | -16.0\% | 6,880.1 | 21.6\% |
| Tax | 173.8 | 1.1\% | 585.2 | 4.0\% | -70.3\% | (1,486.6) | -4.7\% |
| PAT | 2,528.2 | 15.9\% | 2,630.4 | 18.2\% | -3.9\% | 8,366.7 | 26.2\% |
| Non controlling interest | (51.9) | -0.3\% | (0.2) | 0.0\% | -100.0\% | (23.2) | -0.1\% |
| Profit for the Period | 2,580.1 | 16.3\% | 2,630.6 | 18.2\% | -1.9\% | 8,389.9 | 26.3\% |
| Adjusted PAT | 3,454.2 | 21.8\% | 3,829.4 | 26.4\% | -9.8\% | 8,544.1 | 26.8\% |

*Adjusted PAT = Reported PAT + Exceptional Items + Amortization of Kesh King \& other brand related intangible assets. For FY22, it also excludes, MAT credit

## Balance Sheet

| SI. | Equity \& Liabilities | As at 30.09.2022 | As at 31.03.2022 | SI. | Assets | $\begin{array}{\|c\|} \hline \text { As at } 30.09 .2022 \\ \hline \text { Unaudited } \\ \hline \end{array}$ | $\begin{array}{\|c\|} \hline \text { As at 31.03.2022 } \\ \hline \text { Audited } \\ \hline \end{array}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Unaudited | Audited |  |  |  |  |
|  | EQUITY |  |  | 1 | Non -Current Assets |  |  |
| (a) | Equity Share capital | 441 | 441 | (a) | Property, Plant and Equipment | 6,556 | 6,857 |
| (b) | Other Equity | 22,885 | 20,325 | (b) | Capital work-in-progress | 35 | 17 |
|  | Total Equity attributable to owners of the Parent | 23,326 | 20,766 | (c) | Investment Properties | 545 | 541 |
| (c) | Non-Controlling Interest | 107 | -23 | (d) | Other Intangible Assets | 5,205 | 5,601 |
|  | Total Equity | 23,433 | 20,743 | (e) | Goodwill on Consolidation | 843 | 242 |
|  |  |  |  | (f) | Right of Use Assets | 199 | 198 |
|  | LIABILITIES |  |  | (g) | Intangible assets under development | 6 | 14 |
| 1 | Non-Current Liabilities |  |  | (h) | Financial Assets |  |  |
| (a) | Financial Liabilities |  |  |  | (i) Investments |  |  |
|  | (i) Lease Liabilities | 100 | 99 |  | a) Investment in Associates | 118 | 561 |
|  | (ii) Other Financial Liabilities | 69 | 69 |  | b) Others | 2,100 | 2,071 |
| (b) | Provisions | 303 | 252 |  | (ii) Loans | 21 | 48 |
| (c) | Deferred Tax Liabilities (Net) | 144 | 75 |  | (iii) Other Financial Assets | 882 | 767 |
| (d) | Other Non-Current Liabilities | 170 | 179 | (i) | Deferred Tax Assets (net) | 3,131 | 2,838 |
|  |  |  |  | (j) | Other Non-Current Assets | 66 | 93 |
|  |  | 786 | 675 |  |  | 19,707 | 19,847 |
| 2 | Current liabilities |  |  |  |  |  |  |
| (a) | Financial Liabilities |  |  | 2 | Current assets |  |  |
|  | (i) Borrowings | 790 | 2,637 | (a) | Inventories | 3,784 | 3,576 |
|  | (ii) Lease Liabilities | 85 | 80 | (b) | Financial Assets |  |  |
|  | (ii) Trade Payables |  |  |  | (i) Investments | 1,109 | 395 |
|  | Total oustanding dues of Micro \& Small Enterprises | 289 | 337 |  | (ii) Trade Receivables | 3,501 | 3,209 |
|  | Total oustanding dues of creditors Other than Micro \& Small Enterpri | 3,910 | 3,750 |  | (iii) Cash \& Cash Equivalents | 377 | 276 |
|  | (iii) Other Financial Liabilities | 771 | 585 |  | (iv) Bank Balances other than (iii) above | 1,010 | 884 |
| (b) | Other Current Liabilities | 366 | 254 |  | (v) Loans | 64 | 38 |
| (c) | Provisions | 1,159 | 1,344 |  | (vi) Other Financial Assets | 286 | 457 |
| (d) | Current Tax Liabilities (Net) | 147 | 170 | (c) | Current Tax Assets (Net) | 17 | 9 |
|  |  |  |  | (d) | Other Current Assets | 1,879 | 1,884 |
|  |  | 7,516 | 9,157 |  |  | 12,027 | 10,728 |
|  | Total Equity and Liabilities | 31,734 | 30,575 |  | Total Assets | 31,734 | 30,575 |

## Awards \& Accolades



BoroPlus felicitated as one of the 'Iconic Brands of India' at the 5th edition of "The Economic Times

Iconic Brands of India"


Emami's manufacturing unit at Pacharia awarded as "Greentech Environment Award 2022"- for two
times in a row .

## Thank you

